Page last updated: 2024-12-05

pristane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pristane is a branched alkane with the chemical formula C19H40. It is a colorless, odorless liquid that is found in various natural sources, including petroleum, shark liver oil, and some bacteria. Pristane is a significant component of the oil from certain shark species, particularly the basking shark, and has been investigated for its potential health benefits.

Pristane is not naturally synthesized by humans or most animals. It is primarily produced by certain types of bacteria through the degradation of chlorophyll. This process involves the breakdown of the phytol side chain of chlorophyll, which is a complex organic molecule essential for photosynthesis.

Pristane can be synthesized in the laboratory through several methods, including the catalytic hydrogenation of squalene, a naturally occurring unsaturated hydrocarbon found in plants and animals. The synthesis of pristane involves a series of chemical reactions designed to transform squalene into its fully saturated form, pristane.

Pristane has been studied for its potential effects on the immune system. It has been found to induce the production of antibodies and to stimulate the activity of immune cells. This has led to research exploring its potential use in vaccines and as an adjuvant to enhance immune responses.

Pristane has been linked to the development of autoimmune diseases in some cases. Research has shown that injections of pristane into laboratory animals can induce autoimmune disorders, such as lupus and rheumatoid arthritis. This finding has raised concerns about the potential risks associated with pristane, particularly in individuals with a predisposition to autoimmune diseases.

Pristane's presence in the environment has also been a subject of investigation. Its occurrence in petroleum and its potential release during oil spills have raised concerns about its potential impact on marine ecosystems. Studies have explored the effects of pristane on marine organisms, including fish and invertebrates, and the potential for bioaccumulation within food chains.

Pristane is a valuable tool in scientific research, particularly in the fields of immunology, toxicology, and environmental science. Its unique chemical structure and biological properties make it a suitable model compound for studying various physiological and pathological processes. Researchers use pristane to investigate immune responses, evaluate the toxicity of compounds, and understand the fate and effects of pollutants in the environment.

Furthermore, pristane has been explored for potential applications in medicine and biomedicine. Its ability to modulate the immune system has prompted investigations into its potential use in vaccines and as a treatment for certain immune deficiencies. However, its potential risks, particularly the association with autoimmune diseases, warrant further research and careful consideration before any therapeutic applications.'

pristane: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pristane : A norterpene that is an acyclic saturated hydrocarbon derived from phytane by loss of its C-16 terminal methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15979
CHEBI ID53181
MeSH IDM0053419

Synonyms (44)

Synonym
nsc 114852
2,6,10,10-tetramethylpentadecane
brn 1720538
2,6,10,14-tetramethylpentadecane
einecs 217-650-8
2,6,10,14-tetramethyl-pentadecane
pentadecane, 2,6,10,14-tetramethyl-
pristane
nsc-114852
norphytan
1921-70-6
norphytane
nsc114852
pristan
2,10,14-tetramethylpentadecane
pentadecane,6,10,14-tetramethyl-
pristane, synthetic, liquid, sterile-filtered, bioreagent
pristane, synthetic, >=98% (gc)
CHEBI:53181 ,
T0149
unii-26hzv48dt1
hsdb 8345
26hzv48dt1 ,
3-01-00-00570 (beilstein handbook reference)
FT-0610506
AKOS025294812
pristane [mi]
pristane [inci]
norphytane, robuoy
2,6,10,14 tetramethylpentadecane
W-201712
mfcd00008952
meso-pristane
DTXSID70870919 ,
pristane(tm), synthetic 2,6,10,14-tetramethylpentadecane molecular biology reagent
dtxcid80818600
meso-form
Q425446
D92308
SY051769
STARBLD0009645
CS-0138139
norphytane;tmpd
HY-N7819

Research Excerpts

Overview

Pristane is a saturated terpenoid alkane and has become the most popular laboratory model for inducing lupus in mice. It is a naturally occurring isoprenoid that is believed to be derived from the phytyl moiety of chlorophyll.

ExcerptReferenceRelevance
"Pristane is a saturated terpenoid alkane and has become the most popular laboratory model for inducing lupus in mice."( Preclinical Testing of Viral Therapeutic Efficacy in Pristane-Induced Lupus Nephritis and Diffuse Alveolar Hemorrhage Mouse Models.
Awo, EA; Burgin, M; Guo, Q; Lucas, AR; Schutz, LN; Yaron, JR; Zhang, L, 2021
)
1.59
"Pristane is a hydrocarbon oil that is used as a chemical carcinogen to induce tumorigenesis in mice as well as arthritis and lupus nephritis in rats."( Pristane-induced mammary carcinomas.
Lee, BH; Shetti, D, 2021
)
2.79
"Pristane-induced lupus is a well-established model of murine lupus. "( Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus.
Chowdhary, VR; David, CS; Grande, JP; Luthra, HS, 2007
)
2.01
"Pristane is a naturally occurring isoprenoid that is believed to be derived from the phytyl moiety of chlorophyll. "( Analysis of transcriptional activation of a cyclic AMP response element by 2,6,10,14-tetramethylpentadecane (pristane) in JB6 mouse epidermal cells.
Ackland-Berglund, C; Banbura, M; Hamernik, D; Jones, C; Lee, SH, 1994
)
1.94
"Pristane is a naturally occurring isoprenoid which is believed to be derived from the phytyl moiety of chlorophyll. "( The tumor promoter pristane activates transcription by a cAMP dependent mechanism.
Ackland-Berglund, CE; Jones, CJ; Lee, SH, 1992
)
2.05

Effects

ExcerptReferenceRelevance
"The pristane model of SLE has the capacity to reproduce many components of the human presentation of the disease."( Preclinical Testing of Viral Therapeutic Efficacy in Pristane-Induced Lupus Nephritis and Diffuse Alveolar Hemorrhage Mouse Models.
Awo, EA; Burgin, M; Guo, Q; Lucas, AR; Schutz, LN; Yaron, JR; Zhang, L, 2021
)
1.35

Treatment

Pristane-treated mice chronically produce high levels of anti-ribonucleoprotein/Smith (anti-Sm/RNP) and other lupus autoantibodies. The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta.

ExcerptReferenceRelevance
"Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15)."( MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus.
Blüml, S; Gessl, I; Jacobs, B; Kiss, A; Kozakowski, N; Leiss, H; Podesser, BK; Puchner, A; Salzberger, W; Smolen, JS; Stummvoll, GH, 2017
)
1.39
"In pristane-treated TNFα(-/-) mice, the numbers of neutrophils, a cell type that promotes resolution of inflammation, were decreased considerably, whereas the responses of inflammatory monocytes and PDCs and the production of type I IFN were increased and prolonged."( Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model.
Han, S; Liu, C; Massini, J; Mathews, CE; Reeves, WH; Wang, H; Xu, Y; Yang, L; Zhuang, H, 2015
)
0.93
"Pristane-treated B6 mice develop severe DAH within 2 weeks of treatment."( In Vivo Therapeutic Success of MicroRNA-155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage.
Brohawn, P; Harley, JB; Higgs, BW; Huang, X; Jallal, B; Jia, Q; Liu, Z; Meng, Y; Qu, B; Shen, N; Tang, Y; Wang, Y; Xiao, C; Yao, Y; Zhou, S, 2016
)
1.16
"Pristane-treated mice chronically produce high levels of anti-ribonucleoprotein/Smith (anti-Sm/RNP) and other lupus autoantibodies. "( Maintenance of autoantibody production in pristane-induced murine lupus.
Choi, HS; Han, S; Lee, P; Li, Y; Reeves, WH; Sun, Y; Vidal, O; Wilson, JC; Xu, Y; Yang, LJ; Zhuang, H, 2015
)
2.12
"Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice."( Psgl-1 Deficiency is Protective against Stroke in a Murine Model of Lupus.
Eitzman, DT; Guo, C; Hodgin, JB; Kleiman, K; Knight, JS; Wang, H; Wang, J, 2016
)
1.16
"The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice."( Development of pristane induced mice model for lupus with atherosclerosis and analysis of TLR expression.
Chen, X; Cui, R; Huang, Z; Li, R; Lin, H; Lin, L,
)
0.97
"Pristane treatment in SNF1 mice accelerated the onset and progression of proteinuria, autoantibody production, immune complex deposition and development of renal lesions."( Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.
Allaire, N; Bajko, J; Browning, JL; Chou, WC; Czerkowicz, JM; Dunstan, RW; Fu, K; Gardet, A; Kerns, HM; Lafyatis, R; Legault, HM; Lukashev, M; Rabah, D; Ranger, AM; Reynolds, TL; Ryan, S; Velez, DB; Viney, JL, 2016
)
2.6
"In pristane-treated DA rats the MHC class II beta-chain, gelatinase B (Mmp9) and the protein tyrosine phosphatase CL100 (Ptpn16) were expressed at a higher level, whereas immunoglobulins, the CD28 molecule (Cd28), the mast cell specific protease 1 (Mcpt1), the carboxylesterase precursor (Ces2), K-cadherin (Cdh6), cyclin G1 (Ccng1), DNA polymerase IV (Primase) and the tumour associated glycoprotein E4 (Tage) were expressed at a lower level."( Differential gene expression in pristane-induced arthritis susceptible DA versus resistant E3 rats.
Holmberg, J; Holmdahl, R; Ibrahim, S; Koczan, D; Olofsson, P; Thiesen, HJ; Wester, L, 2003
)
1.12
"Pristane treatment increased the levels of IgG anti-chromatin antibodies in nu/nu mice, but did not induce production of anti-nRNP/Sm or -Su antibodies."( Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
Jennette, JC; Kanwar, YS; Okano, T; Reeves, WH; Richards, HB; Satoh, M, 1999
)
1.25
"Pristane oil treatment was started at 4 to 6 weeks of age (3 x 0.3 ml via i.p."( Plasmacytoma induction in specific pathogen-free (SPF) bcl-2 transgenic BALB/c mice.
Klein, G; Silva, S, 1999
)
1.02
"Pristane-treated B6 mice developed anti-nRNP/Sm, Su, and ribosomal P Abs, but little anti-ssDNA or chromatin."( Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.
Reeves, WH; Richards, HB; Satoh, M; Shaheen, VM; Shaw, M; Weintraub, JP; Yoshida, H, 2000
)
1.27
"When treated with pristane, TNFα(-/-) mice developed more severe lupus compared to pristane-treated controls, characterized by increased levels of anti-Sm/RNP autoantibodies, type I IFN, PDCs, and peritoneal inflammatory (Ly-6C(high) ) monocytes."( Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model.
Han, S; Liu, C; Massini, J; Mathews, CE; Reeves, WH; Wang, H; Xu, Y; Yang, L; Zhuang, H, 2015
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
" Those mice were treated with pristane alone or combined with chloroquine."( Effects of pristane alone or combined with chloroquine on macrophage activation, oxidative stress, and TH1/TH2 skewness.
Chen, X; Huang, Z; Lin, L; Ni, J; Ouyang, Q; Wang, Z, 2014
)
1.08

Bioavailability

ExcerptReferenceRelevance
" The objectives of this study was aimed to determine the correlation among bioavailability of petroleum hydrocarbons, SOM content, and DOM level in soil-water systems."( Effects of natural organic matters on bioavailability of petroleum hydrocarbons in soil-water environments.
Chen, CH; Liu, PG; Whang, LM, 2019
)
0.51
" The results also conclude that addressing the bioavailability of resveratrol using it in combination with piperine does not prove more efficacious in preventing lupus-associated pathologies than resveratrol alone."( Prophylactic effect of resveratrol and piperine on pristane-induced murine model of lupus-like disease.
Bhatnagar, A; Pannu, N, 2020
)
0.81

Dosage Studied

Pristane-induced arthritis (PIA) was produced in male CBA mice dosed with anti-OSM or control immunoglobulin immediately before disease onset.

ExcerptRelevanceReference
" Thus, for the application of nasal 'tolerance' in clinical medicine, it is important to identify antigens and dosing regimes that counteract but do not activate adverse immune responses."( The route of administration of an immunodominant peptide derived from heat-shock protein 65 dramatically affects disease outcome in pristane-induced arthritis.
Francis, JN; Lamont, AG; Thompson, SJ, 2000
)
0.51
" Pristane-induced arthritis (PIA) was produced in male CBA mice dosed with anti-OSM or control immunoglobulin immediately before disease onset."( Amelioration of arthritis in two murine models using antibodies to oncostatin M.
Buckton, J; Life, PF; Papworth, J; Plater-Zyberk, C; Spaull, J; Thompson, S; Zanders, E, 2001
)
1.22
" Therapeutic studies were performed for up to 8 weeks of dosing with prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB242235, and human soluble TNF receptor (sTNFR; etanercept) and murine sTNFR fusion proteins."( Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
Bush, K; Life, P; Morgan, R; Patten, C; Rioja, I; Trill, J; Wooley, P, 2004
)
0.65
"5 ml of pristane and after 2 months they were orally dosed with resveratrol combinations for 4 months."( Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus.
Bhatnagar, A; Pannu, N, 2020
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
biomarkerA substance used as an indicator of a biological state.
immunological adjuvantA substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
norterpeneAny hydrocarbon formed by loss of a methyl group from a terpene.
long-chain alkaneAny alkane having a chain length of at least 13 carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (499)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (11.82)18.7374
1990's128 (25.65)18.2507
2000's104 (20.84)29.6817
2010's145 (29.06)24.3611
2020's63 (12.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.38 (24.57)
Research Supply Index6.23 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews15 (2.96%)6.00%
Case Studies1 (0.20%)4.05%
Observational1 (0.20%)0.25%
Other489 (96.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]